News | RSNA | December 24, 2019

Alzheimer’s Disease AI Research Receives RSNA Margulis Award

The Radiological Society of North America (RSNA) presented its eighth Alexander R. Margulis Award for Scientific Excellence to Jae Ho Sohn, M.D., from the Radiology & Biomedical Imaging Department at the University of California in San Francisco (UCSF)

Jae Ho Sohn, M.D.

December 24, 2019 — The Radiological Society of North America (RSNA) presented its eighth Alexander R. Margulis Award for Scientific Excellence to Jae Ho Sohn, M.D., from the Radiology & Biomedical Imaging Department at the University of California in San Francisco (UCSF), for the article, “A Deep Learning Model to Predict a Diagnosis of Alzheimer Disease by Using 18F-FDG PET of the Brain,” published online in November 2018. The groundbreaking study shows the significant potential of artificial intelligence (AI) as a diagnostic tool in Alzheimer’s disease (AD). Sohn was presented with the award today at RSNA 2019 in Chicago.

Named for Alexander R. Margulis, M.D., a distinguished investigator and inspiring visionary in the science of radiology, this annual award recognizes the best original scientific article published in RSNA’s peer-reviewed journal Radiology.

A radiology resident with an engineering background,  Sohn co-authored the study with the goal of developing a deep learning algorithm to detect patterns on complex brain images to identify AD as early as possible.

“Alzheimer’s is a costly, devastating disease and by the time a clinical diagnosis is made, it’s often too late,” said Sohn, who leads the UCSF Big Data in Radiology (BDRAD) multidisciplinary team of physicians and engineers focusing on radiological data science. “We hypothesized we could use AI as an early prediction tool for Alzheimer’s in conjunction with other biochemical and imaging tests. If we can detect the disease early enough, physicians have a chance of slowing it down or halting it through therapeutic intervention.”

The results far exceeded Sohn’s expectations. Using 18F fluorodeoxyglucose (FDG) PET scans to train a deep learning algorithm, Sohn and colleagues were able to detect early-stage AD about six years before it was clinically diagnosed.

“This research is groundbreaking,” said Radiology editor David A. Bluemke, M.D. “It demonstrates the potential for state-of-the-art AI technology to help interpret the remarkably complex patterns on FDG PET imaging in patients with Alzheimer's disease. Even more hopeful for Alzheimer’s patients, this same line of research will also apply to more specific PET tracers for detecting the disease.”

The study began when UCSF colleagues Benjamin Franc, M.D., a nuclear medicine specialist, and Youngho Seo, Ph.D., a nuclear medicine physicist, approached Sohn and undergraduate student Yiming Ding about developing an algorithm to interpret FDG PET brain scans. Research has linked the disease process to changes in metabolism, which can be difficult to recognize. PET scans can measure the uptake of FDG in brain cells, indicating metabolic activity.

The research team used data from the Alzheimer’s Disease Neuroimaging Initiative (ADNI), a major multi-site study focused on clinical trials to improve prevention and treatment of this disease. The ADNI dataset included more than 2,100 FDG PET brain images from 1,002 patients. The researchers trained the deep learning algorithm on 90 percent of the dataset and then tested it on the remaining 10 percent of the dataset.

Finally, they tested the algorithm on an independent set of 40 FDG PET imaging exams from 40 patients that it had never studied. Results showed that algorithm achieved 82 percent specificity and 100 percent sensitivity at detecting the disease an average of more than six years prior to the final diagnosis.

“I was surprised at how high the numbers were, but I already knew AI was going to be more effective than humans,” Sohn said. “The very special nature of AI detects very global, subtle changes that the human eye cannot.”

Sohn, who plans to continue researching the vast capabilities of AI in radiology, was extremely honored to be chosen for Margulis Award, which he believes will open doors for future research.

“I was completely surprised and shocked to receive the award,” Sohn said. “This recognition will pave the way for my research career and will allow me to connect with other researchers doing important work.”

Sohn stresses that further validation with larger and prospective external tests must be performed before the Alzheimer’s detection algorithm can be used clinically. However, he believes that researchers united in the fight against Alzheimer’s are on the brink of a significant breakthrough.

“I really think we are at an inflection point with Alzheimer’s disease,” Sohn said. “I believe we will see major progress in the next decade or two.”

Access the study at https://pubs.rsna.org/doi/10.1148/radiol.2018180958.  

Related content:

Clinical Implementation of Artificial Intelligence in Radiology

Related Content

Detroit-based magnetic resonance imaging (MRI) technology company SpinTech, Inc. has acquired medical-imaging research and technology developer Magnetic Resonance Innovations, Inc. (MR Innovations).
News | Magnetic Resonance Imaging (MRI) | February 24, 2021
February 24, 2021 — Detroit-based magnetic resonance...
Findings indicate that PPC and GG are highly predictive of overall upstaging by PSMA PET/CT for patients with high-risk prostate cancer

Image courtesy of UCLA Health

News | PET-CT | February 23, 2021
February 23, 2021 — A...
icobrain cva allows the quantitative assessment of tissue perfusion by reporting the volume of core and perfusion lesion by quantifying Tmax abnormality and CBF abnormality together with the mismatch volume and ratio
News | Artificial Intelligence | February 23, 2021
February 23, 2021 — icometrix, world leader in imaging...
F-18 FES PET images of patients with ER+/PR+/HER2- invasive ductal carcinoma. Left panel: Progressive disease seen at the 8-week time-point in a patient on sequential therapy. Right panel: Stable disease through all 3 time-points, remaining on study therapy for 6.7 months until disease progression on combined vorinostat aromatase inhibitor therapy. Image created by Lanell M Peterson, Research Scientist, University of Washington Medical Oncology, Seattle WA.

F-18 FES PET images of patients with ER+/PR+/HER2- invasive ductal carcinoma. Left panel: Progressive disease seen at the 8-week time-point in a patient on sequential therapy. Right panel: Stable disease through all 3 time-points, remaining on study therapy for 6.7 months until disease progression on combined vorinostat aromatase inhibitor therapy. Image created by Lanell M Peterson, Research Scientist, University of Washington Medical Oncology, Seattle WA.

News | Molecular Imaging | February 22, 2021
February 22, 2021 — Molecular imaging
Dr Sahar Saleem placing the mummy in the CT scanner

Dr. Sahar Saleem placing the mummy in the CT scanner. Image courtesy of Sahar Saleem

News | Computed Tomography (CT) | February 22, 2021
February 22, 2021 — Modern medical technology is helping scholars tell a more nuanced story about the fate of an anci
Axial FLAIR MR image shows T2 prolongation in bilateral middle cerebellar peduncles (arrows). Findings were associated with restricted diffusion and areas of T1 hypointense signal without enhancement or abnormal susceptibility. Image courtesy of American Roentgen Ray Society (ARRS), American Journal of Roentgenology (AJR)

Axial FLAIR MR image shows T2 prolongation in bilateral middle cerebellar peduncles (arrows). Findings were associated with restricted diffusion and areas of T1 hypointense signal without enhancement or abnormal susceptibility. Image courtesy of American Roentgen Ray Society (ARRS), American Journal of Roentgenology (AJR)

News | Coronavirus (COVID-19) | February 22, 2021
February 22, 2021 — According to an...
Examples of the imaging performance of XPCI-CT (b,e) compared to conventional specimen radiography (a,d) and benchmarked against histopathology (c,f). he top row focuses on the similarity between the XPCI-CT slice in (b) and the histological slice in (c). Arrow 1 indicates margin involvement, arrow 2 a variation in density in the internal structure of the tumour mass, arrow 3 tumour-induced inflammation. All this is confirmed by the histological slice in (c), and hardly visible in the conventional image in

Examples of the imaging performance of XPCI-CT (b,e) compared to conventional specimen radiography (a,d) and benchmarked against histopathology (c,f). he top row focuses on the similarity between the XPCI-CT slice in (b) and the histological slice in (c). Arrow 1 indicates margin involvement, arrow 2 a variation in density in the internal structure of the tumour mass, arrow 3 tumour-induced inflammation. All this is confirmed by the histological slice in (c), and hardly visible in the conventional image in (a). The bottom row focuses on the detection of small calcifications, a key feature in DCIS. These are undetectable in (d), detected in (e), enhanced in the maximum intensity projection (MIP) image at the bottom of (f), and confirmed by histopathology in the top part of (f). The scale bar [shown in (b) and (e)] is the same for all images apart from (f), which has its own scale. Red arrows in (e) and (f) indicate the microcalcifications. Image courtesy of Professor Alessandro Olivo

News | Breast Imaging | February 22, 2021
February 22, 2021 — A new X-ray imaging scanne
 Enterprise imaging systems provider Intelerad Medical Systems announced it has acquired Lumedx, a leading provider of healthcare analytics and cardiovascular information systems (CVIS). 
News | Enterprise Imaging | February 18, 2021
February 18, 2021 – Enterprise imaging systems provider Intelerad Medical Systems announced it has acquired...
GE Healthcare introduced its artificial intelligence (AI) automation features on its Voluson Swift ultrasound platform at the 2020 Radiological Society of North America (RSNA) virtual meeting. Features of this system include semi-automated contouring, auto identification of fetal anatomy and positioning on imaging. AI is seeing increasing integration in ultrasound systems from numerous vendors.

GE Healthcare introduced its artificial intelligence (AI) automation features on its Voluson Swift ultrasound platform at the 2020 Radiological Society of North America (RSNA) virtual meeting. Features of this system include semi-automated contouring, auto identification of fetal anatomy and positioning on imaging. AI is seeing increasing integration in ultrasound systems from numerous vendors.

Feature | Ultrasound Imaging | February 18, 2021 | By Dave Fornell, Editor
Recent advances in ultrasound image sy...